Alterity Therapeutics (NASDAQ:ATHE) versus NovoCure (NASDAQ:NVCR) Head to Head Contrast

Alterity Therapeutics (NASDAQ:ATHE) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Alterity Therapeutics and NovoCure”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87 million	N/A	N/A
NovoCure	$655.35 million	2.23	-$136.23 million	($1.22)	-10.52

Alterity Therapeutics has higher earnings, but lower revenue than NovoCure.

Institutional and Insider Ownership

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Alterity Therapeutics and NovoCure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1	1	1	0	2.00
NovoCure	1	3	3	0	2.29

NovoCure has a consensus target price of $26.93, suggesting a potential upside of 109.89%. Given NovoCure’s stronger consensus rating and higher probable upside, analysts clearly believe NovoCure is more favorable than Alterity Therapeutics.

Profitability

This table compares Alterity Therapeutics and NovoCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
NovoCure	-20.79%	-39.11%	-11.69%

Risk and Volatility

Alterity Therapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

NovoCure beats Alterity Therapeutics on 6 of the 11 factors compared between the two stocks.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.